Navigation Links
FDA Issues Complete Response Letter for INTUNIV(TM) (guanfacine) Extended Release for the Treatment of ADHD in Children and Adolescents
Date:7/28/2009

PHILADELPHIA, July 28 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that it has received a Complete Response letter today for INTUNIV(TM) (guanfacine) Extended Release from the Food and Drug Administration (FDA). This decision comes following labeling discussions with the FDA that did not result in agreement in time to meet the PDUFA date.

The FDA did not identify safety concerns regarding INTUNIV in the Complete Response letter or request new clinical studies. Shire and the FDA will continue to work together to resolve the remaining labeling language over the next 4 to 8 weeks.

"Shire is confident that we will quickly come to agreement on the final product label and anticipates a launch in the fourth quarter as planned," said Mike Cola, President of Shire Specialty Pharmaceuticals. "When approved, INTUNIV will be the first selective alpha-2A receptor agonist for the treatment of ADHD, and will provide patients with an important new treatment option."

About INTUNIV

INTUNIV is being studied for the treatment of ADHD in children and adolescents aged 6 to 17 years. INTUNIV is a once-daily, extended release formulation of guanfacine, designed to provide steady delivery of drug throughout the day. INTUNIV is not a controlled substance and has no known potential for abuse or dependence.

Guanfacine, the active ingredient in INTUNIV, is thought to work directly by binding selectively to alpha-2A adrenergic receptors located in the prefrontal cortex - an area of the brain that has been linked to ADHD.(4-6) Stimulation of the postsynaptic alpha-2A receptors is thought to strengthen working memory, reduce susceptibility to distraction, improve attention regulation, improve behavioral inhibition and enhance
'/>"/>

SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. The First Annual Cervical Cancer/HPV Conference Tackles Controversial Vaccine Issues and Encourages Advocacy
2. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
3. European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg)
4. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
5. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
6. QIAGEN and Center for Molecular Medicine Create Research Collaboration for Molecular Diagnostic Markers for Breast Cancer, Other Womens Health Issues
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Bioniche Life Sciences Inc.
8. Lupus Under the Spotlight: U.S. Congress Shows Support for Womens Health Issues
9. European Unions CHMP Issues Positive Opinion on Sugammadex
10. Newly Published Study Shows OPKOs siRNA Bevasiranib Is Taken Up by Target Tissues in the Eye
11. Ending Cervical Cancer Featured at Summit; QIAGEN CEO Issues a Call to Global Women Leaders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... analysis of Centers for Medicare and Medicaid Services, (CMS) ... percent of seniors chose lower-cost preferred pharmacy plans that ... The findings were released by Drug Channels . ... of Medicare Part D," said Pharmaceutical Care Management Association ...
(Date:1/23/2015)... DUBLIN , Jan. 23, 2015  Immune Therapeutics, Inc. ... Biotechnology, Inc. for the compounding, packaging and distributing of its ... the United States . ... of compounding naltrexone tablets in various strengths for individual patients ...
(Date:1/23/2015)... 23, 2015  Now available for sale, The Armor1 Ankle ... prevents ankle sprains by cushioning the ankle from an ... around the outside of any shoe type and allows ... still offering protection against sprains. With customers in physical ...
Breaking Medicine Technology:New Analysis: 81 Percent of Medicare Part D Seniors Choose "Preferred Pharmacy" Plans in 2015 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4The Armor1 Ankle Roll Guard is the New Breakthrough Solution for Ankle Sprain Prevention! 2
... 2011 /PRNewswire-Asia-FirstCall/ -- Mindray Medical International Limited (NYSE: ... of medical devices worldwide, announced today an agreement to ... Technical Development Co. Ltd. The terms of the transaction ... Mindray,s financial statements. Founded in 2004 and ...
... Nev., Feb. 28, 2011 PDL ... financial results for the fourth quarter and full year ended ... were $345.0 million, compared to $318.2 million in 2009.  Excluding ... royalty revenues for 2010 increased 30 percent over 2009.  For ...
Cached Medicine Technology:Mindray Medical to Acquire a Controlling Stake in Shenke Medical 2Mindray Medical to Acquire a Controlling Stake in Shenke Medical 3Mindray Medical to Acquire a Controlling Stake in Shenke Medical 4PDL BioPharma Announces Fourth Quarter and Full Year 2010 Financial Results 2PDL BioPharma Announces Fourth Quarter and Full Year 2010 Financial Results 3PDL BioPharma Announces Fourth Quarter and Full Year 2010 Financial Results 4PDL BioPharma Announces Fourth Quarter and Full Year 2010 Financial Results 5PDL BioPharma Announces Fourth Quarter and Full Year 2010 Financial Results 6PDL BioPharma Announces Fourth Quarter and Full Year 2010 Financial Results 7PDL BioPharma Announces Fourth Quarter and Full Year 2010 Financial Results 8PDL BioPharma Announces Fourth Quarter and Full Year 2010 Financial Results 9PDL BioPharma Announces Fourth Quarter and Full Year 2010 Financial Results 10
(Date:1/22/2015)... Deer Path of Huntley -- a BMA affordable assisted ... 3 p.m. to 4 p.m. on Feb. 13. , The community, ... adults with physical disabilities between the ages of 22 and 64. ... and sweetheart-themed karaoke. , For more information about the event or ...
(Date:1/22/2015)... LunaDress, with its top dressmaking technologies, has ... the business is showing its latest designs of wedding dresses ... to the company’s CEO, all the fresh new products are ... discounts, up to 80% off. All the clothes from LunaDress ...
(Date:1/22/2015)... Gabe’s Chemo Duck Program is pleased to announce the release ... for kids with cancer. The Chemo Duck App, available on iTunes ... enjoyable games to help children of all ages living with cancer ... keep kids entertained, educated and at ease while waiting for clinic ...
(Date:1/22/2015)... 2015 The Incredible Bulk is a revolutionary ... increase lean muscle by up to 30lbs in less than ... of HealthyandFitZone.com’s Stan Stevenson, prompting an investigative review. , “Our ... step-by-step, scientific diet formula that allows the body to pack ...
(Date:1/22/2015)... the premier women’s dress supplier, has recently released its ... of AngelWeddingDress.com to find more details. , Many ... a bridal party. AngelWeddingDress offers a variety of gorgeous ... wedding dresses are specially designed for 2015. , AngelWeddingDress ...
Breaking Medicine News(10 mins):Health News:Deer Path of Huntley Affordable Assisted Living to Host Valentine's Day Happy Hour 2Health News:LunaDress Shows The Latest Styles Of Wedding Dresses In 2015 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2
... Breast cancer patients treated with intensity modulated radiation therapy ... a lower incidence of acute or chronic toxicities, according ... ( PRO ), the official clinical practice journal of ... constantly conducting studies to determine the most effective breast ...
... By Alan Mozes HealthDay Reporter , MONDAY, March ... procedures to standard diabetes treatments contends that surgery is more ... finding stems from two years of tracking 60 severely obese ... ages of 30 and 60. One-third of the patients were ...
... on 31 March when the ship and crew reach Lorient, ... across all the world,s major oceans to sample and investigate ... Karsenti in an editorial published today in Molecular Systems ... yet we know very little about the distribution of marine ...
... HealthDay Reporter , MONDAY, March 26 (HealthDay News) -- ... lowered LDL cholesterol levels in patients with high cholesterol ... treatment could help lower levels of "bad" cholesterol for ... the commonly prescribed cholesterol-lowering drugs known as statins. It ...
... (HealthDay News) -- Antibiotics can prolong cystic fibrosis patients, ... in their lungs, a new, small study suggests. ... not prove, that the current standard of aggressive antibiotic ... the best approach. It,s common to use antibiotics ...
... HealthDay Reporter , MONDAY, March 26 (HealthDay News) -- ... that people who eat chocolate regularly are somewhat skinnier than ... don,t prove that chowing down on chocolate will melt off ... for the modest difference in body mass, or it might ...
Cached Medicine News:Health News:IMRT reduces risk of side effects in breast cancer patients 2Health News:Weight-Loss Surgeries May Beat Standard Treatments for Diabetes 2Health News:Weight-Loss Surgeries May Beat Standard Treatments for Diabetes 3Health News:Weight-Loss Surgeries May Beat Standard Treatments for Diabetes 4Health News:TARA OCEANS completes 60,000-mile journey to map marine biodiversity 2Health News:New Injection Might Lower Tough-to-Treat Cholesterol 2Health News:New Injection Might Lower Tough-to-Treat Cholesterol 3Health News:Should Cystic Fibrosis Patients Get So Many Antibiotics? 2Health News:Does Chocolate Help You Stay Slim? 2Health News:Does Chocolate Help You Stay Slim? 3
...
Ascent Primary Knee System with cruciate retaining, posterior stabilized and constrained components...
... tricompartmental total knee prosthesis stems from many ... design and manufacturing technologies have been used ... as well as a favorable pressure distribution ... keep wear to a minimum. The inherent ...
The Natural-Knee Family is a complete range of interchangeable, anatomically-designed implants with over 14 years of proven clinical results....
Medicine Products: